# An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease

> **NCT03770299** · PHASE2 · WITHDRAWN · sponsor: **Bristol-Myers Squibb**

## Conditions studied

- Non-Small Cell Lung Cancer
- Non-Small-Cell Lung Carcinoma
- Circulating Tumor DNA

## Interventions

- **BIOLOGICAL:** Nivolumab
- **DRUG:** Vinorelbine
- **DRUG:** Gemcitabine
- **DRUG:** Docetaxel
- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **OTHER:** Observation

## Key facts

- **NCT ID:** NCT03770299
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-01-15
- **Primary completion:** 2023-03-14
- **Final completion:** 2024-03-14
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business objectives have changed
- **Last updated:** 2022-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03770299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03770299, "An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03770299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*